Senolytics

Dasatinib + quercetin shows a targeted senolytic signal in bone aging

July 02, 2024

English digest

What if cleaning out your aging cells could protect your bones — but only if you have enough of them to clean?

Scientists enrolled 60 postmenopausal women in a phase 2 randomized controlled trial and gave them an intermittent course of dasatinib plus quercetin — two drugs that selectively clear senescent cells from the body — over 20 weeks. Before and after treatment, the team measured a panel of bone-resorption markers, a bone-formation marker, and each participant's circulating burden of senescent cells, allowing them to test whether the drug combination worked differently depending on how much senescent-cell load each woman carried going in.

Across the full study group, the combination did not improve the primary bone-resorption endpoint — the headline result was a null finding. But the picture looked different when researchers examined subgroups: in women who started the trial with the highest senescent-cell burden, the treatment produced a more encouraging signal, and the drugs also briefly elevated a marker tied to bone formation. Think of the therapy as targeted weed control — it works best when the weeds are actually plentiful enough to remove. When senescent cells are sparse to begin with, clearing them produces too small a change to move a clinical endpoint.

Continue reading this digest

What they found · Why it matters for longevity

Read full digest →

Premium — $7/month · Cancel anytime

Join 1,200+ readers following longevity science

Source paper

Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial

Read the original paper